Aktiesnakken — Juli 2010
-
update på fremtidig strategi
-
vil GSK have zalutumumab
-
Jan: vi har nye muligheder nu
-
vi har mange gode nye gode stoffer i pipeline
-
den nye strategi kommer i early autumm
-
GSK er bevidste om andre stoffer i pipelinen
-
også om DARAtumumab
-
han går i megakøb
-
han snapper ham af fordi han skal ud og sige køb
-
seriøst
-
GSK very pleased with the Arzerra launch
-
men hvad siger kantinedamen i GSK, Gustav???
-
ville Jan vente med Zalu partner indtil der foreligger data?
-
nej
-
cd38 er i spil også med gsk
-
Everything is completely under control
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind